A tiny photovoltaic chip slipped beneath the retina gave most patients with advanced dry macular degeneration something they had lost: the ability to read letters, numbers, and words on their own. In the PRIMAvera pivotal trial, 38 patients received the PRIMA subretinal implant in one eye, and 32 completed 12-month assessments. Of those 32, twenty-seven could read using prosthetic vision at home, while 26 met the prespecified threshold for clinically meaningful visual acuity improvement. The results, published in the New England Journal of Medicine, represent the first time a retinal prosthesis has restored functional central vision lost to geographic atrophy, the advanced form of dry age-related macular degeneration that has no approved treatment to reverse damage already done.
Why restoring letter-reading ability changes the calculus for macular degeneration
Geographic atrophy destroys the photoreceptor cells in the macula, the part of the retina responsible for sharp central vision. Patients lose the ability to read mail, recognize faces, and perform routine tasks that require fine detail. Current therapies can slow the expansion of atrophy in earlier stages, but none rebuild vision once cells are gone. The PRIMA system works differently: a wireless photovoltaic chip converts infrared light projected by special glasses into electrical pulses that stimulate the remaining inner retinal neurons, bypassing dead photoreceptors entirely.
The trial’s primary endpoint, set before enrollment began, was clinically meaningful improvement in visual acuity from baseline at month 12. According to the NEJM report, 26 of 32 assessed patients cleared that bar, a success rate of 81 percent on standardized ETDRS letter charts read at one meter. A separate functional measure captured real-world impact: 84.4 percent of assessed patients, or 27 of 32, could read letters, numbers, and words at home using prosthetic vision alone, as detailed in the home-reading analysis. That distinction matters because chart-based acuity in a clinic does not always predict what patients can do with their vision at the kitchen table.
The device was developed through research led by Daniel Palanker at Stanford University, and the trial was sponsored by Science Corporation, according to the ClinicalTrials.gov registry record. The registry confirms that enrollment, primary endpoint, and sponsor remained unchanged from the original protocol, an important detail for evaluating whether the study was designed to test a genuine hypothesis or retrofitted to match favorable data.
How the PRIMAvera data stack up against earlier PRIMA results
The PRIMAvera trial did not emerge from a vacuum. Earlier feasibility studies of the PRIMA implant in smaller patient groups established that letter-reading gains could persist well beyond the first year. A separate follow-up study tracked prosthetic visual acuity out to 48 months after implantation and found that improvements in letter recognition held steady over that period, as reported in the long-term durability cohort. Those durability data, drawn from a distinct group of patients, gave researchers enough confidence to launch the larger pivotal trial.
The PRIMAvera cohort itself was modest in size: 38 patients implanted across multiple sites, with 32 reaching the 12-month assessment window. Six patients did not complete the evaluation period, and the published reports summarize adverse events without itemizing them patient by patient. That gap limits outside reviewers’ ability to weigh safety against efficacy in granular detail. Still, the fact that the trial met its prespecified primary endpoint with a large majority of completers is a strong signal for a first-of-its-kind device in this disease.
Another nuance is the learning curve. Patients must adapt to a new kind of vision that blends residual natural input from the untreated retina with the patterned stimulation produced by the chip. Training protocols in the trial included repeated sessions to help participants interpret prosthetic signals as letters and words. The persistence of gains in earlier feasibility work suggests that once patients pass this learning phase, their ability to use the device remains stable for years, but PRIMAvera will need longer follow-up to confirm similar durability in a broader population.
One question the existing data raise but do not answer is whether implanting a second device in the fellow eye would produce additional, measurable gains. Each patient in PRIMAvera received the chip in only one eye. Patients with geographic atrophy typically have bilateral disease, meaning the untreated eye continues to lose function. If a unilateral implant restores enough acuity for letter reading, a bilateral approach could, in theory, improve reading speed and depth perception. Preprint data from the PRIMA research program, available through earlier posted prosthetic-vision analyses, describe the testing framework used to measure prosthetic acuity but do not include bilateral implantation outcomes. No published trial protocol currently tests that hypothesis within a controlled 24-month window.
Open questions about cost, access, and long-term performance
The clinical evidence is encouraging, but several practical unknowns stand between trial success and widespread patient access. No primary source in the published record provides data on the cost of the PRIMA system, insurance coverage pathways, or the surgical training infrastructure needed to perform the implantation safely at scale. For patients with geographic atrophy who are weighing their options, this information gap is significant. A device that works in a controlled trial setting still has to clear regulatory review, reimbursement negotiations, and real-world logistics before it can be offered routinely.
Regulators will likely focus on three main issues: durability of benefit, robustness of safety data, and generalizability. Durability will require longer follow-up in the pivotal cohort to confirm that letter-reading gains do not erode with time or with progressive atrophy around the implant. Safety will hinge on detailed accounting of surgical complications, inflammation, and device failures, ideally with standardized definitions that allow comparison to other intraocular procedures. Generalizability means demonstrating that outcomes seen in specialized centers can be replicated in community settings once surgeons beyond the original trial sites begin performing the procedure.
Access will depend not only on price but also on how health systems value functional improvements like independent reading. Payers have historically been more comfortable reimbursing drugs that slow disease progression than devices that restore partial function in advanced stages, especially when long-term outcomes are still being defined. Clear evidence that patients can resume key daily activities-managing medications, reading bills, communicating by email or text-may be crucial for positioning the implant as more than a marginal quality-of-life intervention.
Equity is another concern. Geographic atrophy disproportionately affects older adults, many of whom live on fixed incomes and may have limited access to specialty eye care. If implantation requires travel to a small number of high-volume centers, patients in rural or underserved areas could be left behind. Building a sustainable network of trained surgeons, rehabilitation specialists, and follow-up clinics will be as important as the engineering advances inside the chip itself.
Finally, the PRIMAvera results will shape expectations for future retinal prostheses. Demonstrating that a tiny photovoltaic array can restore functional central vision in a disease long considered irreversible reframes what is possible for neurodegenerative conditions of the eye. At the same time, the technology does not restore normal sight; patients in the trial gained the ability to read and recognize symbols, not to drive or navigate unfamiliar environments unaided. Communicating those limits clearly will be essential to avoid overpromising as the field moves from early adopters toward broader clinical use.
For now, the pivotal data mark a turning point. In a group of people who had exhausted existing options, most regained a practical, measurable form of central vision that had been written off as permanently lost. Whether health systems, regulators, and manufacturers can translate that breakthrough into accessible care will determine how many patients with geographic atrophy ultimately benefit from the tiny chip under the retina.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
